MCET (MultiCell Technologies) ROE % Adjusted to Book Value: 0.00% (As of Aug. 2015)


What is MultiCell Technologies ROE % Adjusted to Book Value?

MultiCell Technologies MCET -90.00% ROE % Adjusted to Book Value is 0.00% as of Aug. 2015.

MultiCell Technologies's ROE % for the quarter that ended in Aug. 2015 was 0.00%. MultiCell Technologies's PB Ratio for the quarter that ended in Aug. 2015 was N/A. MultiCell Technologies's ROE % Adjusted to Book Value for the quarter that ended in Aug. 2015 was N/A.

MultiCell Technologies ROE % Adjusted to Book Value Related Terms

MultiCell Technologies ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies ROE % Adjusted to Book Value Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity 0.00 0.00 Negative Equity 0.00

MCET vs ERGO, OPLI, GLAG: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, MultiCell Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MultiCell Technologies ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's ROE % Adjusted to Book Value falls into.


MultiCell Technologies ROE % Adjusted to Book Value Calculation

MultiCell Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Nov. 2014 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

MultiCell Technologies's ROE % Adjusted to Book Value for the quarter that ended in Aug. 2015 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
MultiCell Technologies (MCET) has a ROE % Adjusted to Book Value of 0.00% as of Aug. 2015. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' ROE % Adjusted to Book Value too high?
MultiCell Technologies' current ROE % Adjusted to Book Value is 0.00%.
How does MultiCell Technologies' ROE % Adjusted to Book Value compare to ERGO and OPLI?
MultiCell Technologies' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MultiCell Technologies and its competitors. MultiCell Technologies's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current ROE % Adjusted to Book Value is 0.00% as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.